SMART-VERAPAF: Self-MAnagement and Random Therapy With VERApamil or Metoprolol in Paroxysmal Atrial Fibrillation

7.2 Inclusion criteria In order to be eligible to participate in this study, a subject must meet all of the following criteria: * Age ≥ 18 years old * ECG documented diagnosis of paroxysmal AF * Presence of symptomatic paroxysmal AF, defined as recurrent self-terminating AF (≥ 2 episodes in last 4 months) documented by typical symptoms, ECG or photoplethysmo-gram * Able and willing to sign informed consent. For SMART sub study only: \- Own a smartphone 7.3 Exclusion criteria A potential subject who meets any of the following criteria will be excluded from participation in this study: * A history of electrical cardioversion for persistent AF * History of AF episode \> 7 days * Previous or current chronic amiodaron use. * A history of pulmonary vein ablation * Taking part in another randomized trial * Reduced life-expectancy of \< 1 year * Presence of contra-indication for verapamil or metoprolol * Pregnant or breastfeeding women. Or women who are planning to become pregnant during the study period. * For substudy patients: already participating in an eHealth program Contraindications for verapamil or metoprolol: * Known hypersensitivity, intolerance or allergy to verapamil, metoprolol, or any excipi-ents. * Current use of verapamil, diltiazem, beta-blockers or digoxin, or \< 5 half-lives ago at the time of randomization. * Concomitant use of medications with absolute contraindications for verapamil or metoprolol (e.g., strong CYP3A4 inhibitors).\* * Resting heart rate…